Nacuity Pharmaceuticals, Inc.
Clinical trials sponsored by Nacuity Pharmaceuticals, Inc., explained in plain language.
-
Can an antioxidant pill slow blindness in usher syndrome?
Disease control Not yet recruitingThis phase 3 trial tests whether an experimental drug called NPI-001 can slow the loss of light-sensing cells in the eyes of adults with Usher syndrome, a genetic condition that causes both hearing and vision loss. About 80 participants take either NPI-001 or a placebo twice dail…
Phase: PHASE3 • Sponsor: Nacuity Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New drug aims to preserve sight in rare genetic blindness
Disease control Not yet recruitingThis phase 3 trial tests whether NPI-001, taken twice daily for 24 months, can slow the loss of light-sensing cells in the eyes of adults with Usher syndrome, a genetic condition that causes both hearing and vision loss. About 80 participants will receive either the drug or a pla…
Phase: PHASE3 • Sponsor: Nacuity Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC